Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK (2017) A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomed (Taipei) 7(4):23. https://doi.org/10.1051/bmdcn/2017070423

Article  Google Scholar 

Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hang L (2024) Non-small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 22(4):249–274. https://doi.org/10.6004/jnccn.2204.0023

Article  CAS  PubMed  Google Scholar 

Chattopadhyay S, Moran RG, Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6(2):404–417. https://doi.org/10.1158/1535-7163.Mct-06-0343

Article  CAS  PubMed  Google Scholar 

Tanino R, Tsubata Y, Harashima N, Harada M, Isobe T (2018) Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer. Oncotarget 9(24):16807–16821. https://doi.org/10.18632/oncotarget.24704

Article  PubMed  PubMed Central  Google Scholar 

Wu MF, Hsiao YM, Huang CF, Huang YH, Yang WJ, Chan HW, Chang JT, Ko JL (2010) Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol 5(8):1143–1151. https://doi.org/10.1097/JTO.0b013e3181e0b954

Article  PubMed  Google Scholar 

Chiu LY, Hsin IL, Yang TY, Sung WW, Chi JY, Chang JT, Ko JL, Sheu GT (2017) The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids. Oncogene 36(2):242–253. https://doi.org/10.1038/onc.2016.195

Article  CAS  PubMed  Google Scholar 

Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP (2000) Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 153(2):323–335. https://doi.org/10.1016/s0021-9150(00)00422-6

Article  CAS  PubMed  Google Scholar 

Pérez-Gómez E, Eleno N, López-Novoa JM, Ramirez JR, Velasco B, Letarte M, Bernabéu C, Quintanilla M (2005) Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene 24(27):4450–4461. https://doi.org/10.1038/sj.onc.1208644

Article  CAS  PubMed  Google Scholar 

Schoonderwoerd MJA, Goumans MTH, Hawinkels L (2020) Endoglin: beyond the endothelium. Biomolecules 10(2). https://doi.org/10.3390/biom10020289

Velasco S, Alvarez-Muñoz P, Pericacho M, Dijke Pt, Bernabéu C, López-Novoa JM, Rodríguez-Barbero A (2008) L-and S-endoglin differentially modulate TGFβ1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci 121(6):913–919

Article  CAS  PubMed  Google Scholar 

Galaris G, Montagne K, Thalgott JH, Goujon G, van den Driesche S, Martin S, Mager HJ, Mummery CL, Rabelink TJ, Lebrin F (2021) Thresholds of Endoglin expression in endothelial cells explains vascular etiology in Hereditary Hemorrhagic Telangiectasia Type 1. Int J Mol Sci 22(16). https://doi.org/10.3390/ijms22168948

Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K, Lloyd RV (2011) Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res 31(6):2283–2290

CAS  PubMed  Google Scholar 

Ollauri-Ibáñez C, Núñez-Gómez E, Egido-Turrión C, Silva-Sousa L, Díaz-Rodríguez E, Rodríguez-Barbero A, López-Novoa JM, Pericacho M (2020) Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis. Angiogenesis 23(2):231–247. https://doi.org/10.1007/s10456-019-09703-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laukhtina E, Schuettfort VM, D’Andrea D, Pradere B, Mori K, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann Ncapital Es C, Rajwa P, Zeinler F, Abufaraj M, Moschini M, Zimmermann K, Karakiewicz PI, Fajkovic H, Scherr D, Comperat E, Nyirady P, Rink M, Enikeev D, Shariat SF (2022) Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Mol Carcinog 61(1):5–18. https://doi.org/10.1002/mc.23355

Article  CAS  PubMed  Google Scholar 

Galanis E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU, Campian J, Giannini C, Buckner JC, Wen PY (2022) Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neurooncol Adv 4(1):vdac041. https://doi.org/10.1093/noajnl/vdac041

Article  PubMed  PubMed Central  Google Scholar 

Lakshman M, Huang X, Ananthanarayanan V, Jovanovic B, Liu Y, Craft CS, Romero D, Vary CP, Bergan RC (2011) Endoglin suppresses human prostate cancer metastasis. Clin Exp Metastasis 28(1):39–53. https://doi.org/10.1007/s10585-010-9356-6

Article  CAS  PubMed  Google Scholar 

Henry LA, Johnson DA, Sarrió D, Lee S, Quinlan PR, Crook T, Thompson AM, Reis-Filho JS, Isacke CM (2011) Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome. Oncogene 30(9):1046–1058. https://doi.org/10.1038/onc.2010.488

Article  CAS  PubMed  Google Scholar 

Romero D, Terzic A, Conley BA, Craft CS, Jovanovic B, Bergan RC, Vary CP (2010) Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis 31(3):359–366. https://doi.org/10.1093/carcin/bgp217

Article  CAS  PubMed  Google Scholar 

Craft C, Romero D, Vary C, Bergan R (2007) Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene 26(51):7240–7250

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K, Lackner M, Wischnewsky MB, Crook T, Lo Nigro C, Schmid P (2015) Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer. Br J Cancer 113(6):970–978. https://doi.org/10.1038/bjc.2015.302

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li CH, Ko JL, Hsiao YP, Tsai MH, Lai YC, Hsin IL, Kang YT, Sheu GT, Lin WL, Wu MF (2021) Plasma endoglin is Associated with Favorable Outcome for Pemetrexed-based therapy in Advanced Non-small Cell Lung Cancer. Cancer Manag Res 13:9305–9318. https://doi.org/10.2147/CMAR.S338957

Article  CAS  PubMed  PubMed Central  Google Scholar 

González Muñoz T, Amaral AT, Puerto-Camacho P, Peinado H, de Álava E (2021) Endoglin in the spotlight to treat cancer. Int J Mol Sci 22(6). https://doi.org/10.3390/ijms22063186

Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, Sheu GT, Hsu SL (2011) Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells. Eur J Pharmacol 663(1–3):17–26. https://doi.org/10.1016/j.ejphar.2011.04.057

Article  CAS  PubMed  Google Scholar 

Karimian A, Ahmadi Y, Yousefi B (2016) Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst) 42:63–71. https://doi.org/10.1016/j.dnarep.2016.04.008

Article  CAS  PubMed  Google Scholar 

Kreis NN, Louwen F, Yuan J (2019) The multifaceted p21 (Cip1/Waf1/CDKN1A) in cell differentiation, Migration and Cancer Therapy. Cancers (Basel) 11(9). https://doi.org/10.3390/cancers11091220

Lin YH, Huang YH, Wu MH, Wu SM, Chi HC, Liao CJ, Chen CY, Tseng YH, Tsai CY, Tsai MM, Lin KH (2013) Thyroid hormone suppresses cell proliferation through endoglin-mediated promotion of p21 stability. Oncogene 32(33):3904–3914. https://doi.org/10.1038/onc.2013.5

Article  CAS  PubMed  Google Scholar 

Kim B-G, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ (2021) Novel therapies emerging in oncology to target the TGF-β pathway. J Hematol Oncol 14(1):55. https://doi.org/10.1186/s13045-021-01053-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pawlak JB, Blobe GC (2022) TGF-β superfamily co-receptors in cancer. Dev Dyn 251(1):137–163. https://doi.org/10.1002/dvdy.338

Article  CAS  PubMed  Google Scholar 

Vidal AC, Duong F, Howard LE, Wiggins E, Freedland SJ, Bhowmick NA, Gong J (2020) Soluble endoglin (sCD105) as a Novel Biomarker for detecting aggressive prostate Cancer. Anticancer Res 40(3):1459–1462. https://doi.org/10.21873/anticanres.14088

Article  CAS